Lung carcinogenesis is a multistep process in which normal lung epithelial cells are converted to cancer cells through the sequential acquisition of multiple genetic or epigenetic events. Despite the utility of current genetically engineered mouse (GEM) models of lung cancer, most do not allow temporal dissociation of the cardinal events involved in lung tumor initiation and cancer progression. Here we describe a novel two-switch GEM model for BRAF V600E -induced lung carcinogenesis allowing temporal dissociation of these processes. In mice carrying a Flp recombinaseactivated allele of Braf (Braf FA ) in conjunction with Cre-regulated alleles of Trp53, Cdkn2a, or c-MYC, we demonstrate that secondary genetic events can promote bypass of the senescence-like proliferative arrest displayed by BRAF V600E
Introduction
Lung cancer will kill approximately 160,000 people in the United States in 2015, which is more than the death rates of the next four most common cancers combined (1) . Aberrant proliferation of non-small cell lung cancers (NSCLC) is frequently associated with mutational activation of receptor tyrosine kinase (RTK) signaling including genes encoding transmembrane receptor tyrosine kinases (ALK, EGFR, MET, ROS1) or intracellular signaling proteins such as KRAS or its effectors A-, B-, or C-RAF or PIK3CA (encoding PI3 0 -kinase-a; refs. 2, 3) . BRAF is estimated to be mutated in $9% of NSCLCs, 25% of which express the BRAF T1799A oncogene encoding the BRAF V600E oncoprotein kinase (4) (5) (6) . However, like many cancers, mutational activation of proto-oncogenes such as ERBB1, KRAS, or BRAF is generally accompanied by silencing of tumor suppressor genes (TSG), such as TP53, CDKN2A, or PTEN, that cooperatively serve to promote the step-wise malignant transformation of normal lung epithelial cells to malignant lung cancer cells (5, 6) .
To model BRAF

V600E
-induced lung tumorigenesis, we previously generated Braf CA mice engineered to carry a Cre-activated Braf allele that allows conversion of normal BRAF to BRAF V600E following exposure of cells to viruses encoding Cre recombinase (7, 8) . Expression of BRAF V600E in the distal lung epithelium results in development of benign lung tumors that fail to progress to lung cancer due to the onset of a senescence-like proliferative arrest (8, 9) . Importantly, when TSGs or proto-oncogenes (Trp53, Cdkn2a, Ctnnb1, Pik3ca) are mutated simultaneously in conjunction with BRAF V600E expression, progression to NSCLC is readily observed (8, 9) .
Despite the utility of Braf CA mice to model BRAF
-induced tumorigenesis (8) (9) (10) , we are constrained by our inability to temporally dissociate genetic events that contribute to cancer progression. Somatic recombination of conditional alleles by Cre recombinase is such that oncogene activation and TSG silencing occur simultaneously-a situation that rarely occurs in humans (11) . We therefore wanted to generate a new GEM model of lung cancer in which expression of BRAF V600E could be temporally dissociated from cooperating genetic events that contribute to malignant progression. To do so, we generated mice carrying a Flp-activated allele of Braf (Braf FA ) that allows conversion of normal BRAF to BRAF V600E in response to Flp recombinase. This allele allows investigator control of the order and timing of BRAF V600E expression in combination with mutational alteration of cooperating genes.
Here, we observed that temporal dissociation of BRAF V600E expression from the silencing of TP53 or INK4A-ARF expression resulted in lung adenocarcinomas. Furthermore, TP53 silencing was able to bypass the senescence-like proliferative arrest observed in late-stage BRAF
-initiated benign lung tumors. As it is possible to lose TP53 function prior to acquiring oncogenic mutations such as that observed in Li-Fraumeni patients (12, 13) , we next modeled this phenomenon by inducing BRAF V600E expression after TP53 silencing. This order of events appeared to modestly enhance the aggressiveness of the disease. To explore the consequences of TP53 silencing in lung cancer cells, we generated BRAF V600E 
/TP53
Null lung cancer cell lines in which we could restore TP53 activity. Restoration of TP53 activity did not result in senescence or apoptosis, but in a reversible G 1 cell-cycle arrest that was independent of p19 ARF expression. These results highlight the growing sophistication of GEM models of human cancer and demonstrate the importance of TP53 signaling in restricting malignant progression of BRAF V600E -induced benign lung tumors.
Materials and Methods
Strains of mice and adenoviral infections
The following strains of mice have been previously described: Braf tm1Mmcm aka Braf CA (8) Derivation of lung cancer cell lines, culture, and analysis BRAF V600E lung cancer-derived cell lines were generated by mincing tumor tissue with a sterile razor blade and placing them into media and pelleted by centrifugation. The tissue pellet was resuspended in 5 to 10 mL of 0.25% (w/v) Trypsin-EDTA and digested at 37 C for 20 minutes with intermittent mixing. The digested cell suspension was filtered sequentially through a 100, 70, and finally a 40 mm filter. The final cell pellet was resuspended in 10 mL of DF12/Glutamax (Invitrogen) media supplemented with 10% (v/v) FCS and 1% (v/v) Pen-Strep on collagen-coated plates. Genetic alterations were confirmed either by PCR or by immunoblot.
Proliferation was assayed by plating cells in triplicate and cultured in various combinations of vehicle, 4-hydroxytamoxifen (4-HT), nutlin-3a (Cayman Chemical, 10-20 mmol/L), and PD0325901 (Hansun Trading Co., 1 mmol/L) for 48 to 72 hours and counted using a Countess cell counter (Invitrogen). A two-tailed Student t test was used to determine significance. Crystal violet assays were also used to assess proliferation. Cells were washed with cold PBS twice and fixed with cold methanol for 10 minutes on ice. Following the removal of methanol, cells were stained with 0.05% (w/v) crystal violet in methanol for 10 minutes at room temperature with unbound crystal violet removed by extensive washing with ddH 2 O.
For cell-cycle analysis, cells were seeded at the appropriate densities and treated with various agents for 48 hours. Cells were incubated with 10 mmol/L BrdUrd for 4 hours prior to harvest and analyzed as previously described (20) . All cell culture experiments were repeated at least three times.
Immunoblotting
Immunoblotting was conducted as previously described (9, 20, 21 CIP1 (ThermoPierce); pT202/Y204-ERK1/2, total ERK1/2, pS473-AKT, total AKT, and p53 (FL-393, Santa Cruz). Antigen-antibody complexes were detected using a LiCOR Odyssey Fluorescent System with fluorescent secondary antisera (LiCOR) and analyzed using ImageStudio software.
Immunohistochemistry
Lung tissues sections were prepared as previously described (9, 20) . In addition, endogenous peroxidase activity was quenched with 3% (v/v) H 2 O 2 in methanol for 20 minutes and then blocked in either 5% goat serum or serum-free block (DAKO) for 30 minutes at room temperature. Antibodies were applied overnight at 4 C: CC10, SP-C, and TTF1 (Santa Cruz); BrdUrd (Serotec); p19
Arf and Ki67 (Abcam); pT202/Y204-ERK1/ 2, p53 (Novocastra), p21 (Abcam), and p27 KIP1 (CST). The appropriate secondary was applied followed either by an antiperoxidase or ABC amplification for 30 to 60 minutes at room temperature. Antigen-antibody complexes were detected using a DAB chromagen system (Sigma). PBS with 0.1% (v/v) Tween 20 was used for all washes.
Quantification of tumor burden
Tumor burden was quantified as previously described (9, 20) . Tumor burden was calculated by measuring the area of all tumors and averaged. At least three or more animals were used for each genotype. (7, 8) . Mice were euthanized at 10 weeks postinitiation (p.i.) and analyzed for tumor burden, grade, and expression of lung epithelial markers ( Fig. 1E and F) .
Results
Generation and characterization of
Initiated Braf FA and Braf CA mice developed a similar spectrum of atypical adenomatous hyperplasias (AAH) and benign adenomas as assessed by the grading criteria established by others and adapted by us (20, 22 and Braf CA adenomas displayed a similar proliferative index (Ki67), coexpressed Surfactant Protein-C (SP-C) and Aquaporin V (AQP5) and were negative for Clara Cell antigen (CCA) expression (Fig. 1F ). Immunoblot analysis of tumor lysates from Braf FA or Braf CA mice revealed equivalent activation of the MEK1/2!ERK1/2 MAP kinase pathway (Fig. 1G) tumorigenesis was initiated in BTR mice using Ad-Flp (10 7 pfu). Four weeks p.i., mouse lungs were instilled with 10 7 pfu of Ad-Cre to elicit simultaneous Cre-mediated silencing of TP53 and expression of b-galactosidase (b-gal) from the Rlz reporter. Mice were euthanized for analysis 4 to 6 weeks after Ad-Cre infection with lung tissues examined for b-gal activity as a measure of successful Cre-mediated recombination of the Rlz reporter ( Fig. 2A) .
Control lung tumor-bearing BTR mice displayed no evidence of b-gal activity in the airways, lung epithelium, or in BRAF V600E -induced lung tumors, indicating a low rate of spontaneous recombination of the Rlz reporter. By contrast, b-gal activity was observed in tumor-bearing BTR mice infected with Ad-Cre specifically in the airways (data not shown), lung epithelium, and in a variable, but generally small percentage of cells in BRAF V600E adenomas ( Fig. 2A) (BT) or Braf FA mice were first infected with Ad-Flp (4 Â 10 6 or 10 7 pfu). Four weeks later, these mice were reinfected with AdCre (10 7 pfu) and the lungs were harvested for analysis when the mice were at end-stage. As a control for Flp-or Cremediated recombination, BT mice were infected with an adenovirus that expressed b-gal (Ad-bgal) in lieu of either Ad-Flp or Ad-Cre. At necropsy, the lungs of BT mice had noticeably larger lung tumors compared with Braf FA controls (Fig. 2B ), whereas BT mice infected with Ad-Flp and Ad-bgal had tumors similar to those induced in Braf FA mice. Histopathological analysis confirmed that these large tumors were indeed adenocarcinomas that were highly proliferative (Ki67 expression or BrdUrd incorporation, not shown) relative to Braf FA benign adenomas. Immunohistochemical analysis of phospho-ERK1/2 (pERK) was performed to assess activation of BRAF V600E !MEK!ERK signaling. The level of pERK was generally low in BRAF V600E adenomas arising in either BT or Braf FA mice. By contrast, the majority of BRAF V600E -induced adenocarcinomas arising in BT mice had readily detectable pERK staining. Often these lung cancers displayed variable pERK staining with higher levels of activation detected around apparent invasive edges. Consistent with the results of others, we detected p19 Humans with Li-Fraumeni syndrome are often heterozygous for a mutated germline allele of TP53 and are at high risk for solid tumors, including lung cancer (12, 13) . Consequently, we decided to model this by silencing TP53 expression in the mouse lung prior to the activation of BRAF
V600E
. BT mice were first infected with Ad-Cre (10 7 pfu) at 6 weeks of age to generate a field of lung epithelial cells lacking TP53 expression. Importantly, TP53 silencing in the lung is insufficient to induce any overt lung pathology. Four weeks after Ad-Cre infection, the mice were reinfected with Ad-Flp (4 Â 10 6 or 10 7 pfu) and euthanized for analysis at endstage (Braf
FA ;Trp53
Rev ;BT Rev mice). A number of the BT Rev mice developed multiple large adenocarcinomas in contrast to BT mice, with an average 3.75 versus 1.6 adenocarcinomas/mouse ( Fig. 2D , P < 0.001, two-tailed t test). Although BT Rev mice had an increased multiplicity of large adenocarcinomas, the overall latency of tumor formation was unchanged compared with BT mice in which BRAF V600E expression was induced prior to TP53 silencing (data not shown). Moreover, similar to lung cancers arising in BT mice, these lesions displayed elevated levels of pERK, p19 ARF and were highly proliferative (Fig. 2B) . Interestingly, we observed a single kidney metastasis in a BT Rev mouse. The lung cancer origin of this macroscopic lesion was confirmed by its expression of lung epithelium markers: NKX2.1, AQP5, and SP-C (Fig. 2C) . These markers were not detected in the surrounding kidney tissue.
Next, we generated tumor lysates from BT (8) . To that end, BRAF V600E expression was initiated in 6-week-old BT mice with Ad-Flp and then subsequently infected with Ad-Cre at 4, 6, or !10 weeks. We also included a cohort of BT Rev mice for this experiment in which we silenced TP53 first followed by BRAF V600E activation using the same defined timepoints.
Approximately 10 weeks p.i., BRAF V600E -induced adenomas display evidence of a senescence-like proliferative arrest as evidenced by decreased Ki67 expression (Fig. 2B) or BrdUrd incorporation (Fig. 2E) . These adenomas express inhibitors of the cell division cycle: TP53, p21 CIP1 , and p27
KIP1
, with no evidence of cell death (data not shown). Incidence of adenocarcinomas was highest when TP53 was silenced 4 weeks following initiation of BRAF V600E expression (68%; Supplementary Table S1 ). As the time between recombination events increased, the incidence of adenocarcinomas decreased, dropping to 14.8% at 10þ weeks p. ARF , a regulator of TP53 activity) cooperates to induce lung adenocarcinomas (8) . , as a trigger of cell-cycle arrest in the induction of senescence in IMR-90 human fibroblasts (24, 27) . Similarly, RAF-induced p19 ARF is thought to trigger TP53-dependent cell-cycle arrest in rodent fibroblasts (25, 28) . Hence, we investigated the effects of activating BRAF V600E prior to INK4A/ARF silencing in the lungs of BC mice. BRAF V600E expression was initiated in 6-week-old BC mice with AdFlp and subsequently infected with Ad-Cre 4 to 6 weeks after tumor initiation. Similar to Trp53, silencing of Cdkn2a alone did not elicit any overt pathology in the lung. Histopathological analysis confirmed that the large lung tumors that formed in suitably manipulated BC mice were indeed adenocarcinomas as evidenced by the presence of invasive fronts, high levels of nuclear atypia, and loss of differentiation. These tumors displayed readily detectable levels of pERK and were highly proliferative (Ki67). Some of these adenocarcinomas also expressed detectable levels of TP53 (Fig. 3A) . Perhaps surprisingly, lung adenocarcinomas arising in BC mice appeared less differentiated than those arising in BT mice as they displayed regions of diminished expression of NKX2.1 and SP-C (Fig. 3B) . Immunoblot analysis of lung tumor-derived lysates from BC mice confirmed effective recombination of Cdkn2a as evidenced by the lack of p19 ARF expression. Consistent with IHC staining, tumors arising in BC mice displayed readily detectable pERK and TP53 expression when compared with BRAF V600E benign adenomas in Braf FA mice (Fig. 3C) . Although Ad-Cre can infect cells in BRAF V600E -initiated tumors in Braf FA mice, the efficiency of secondary infection is generally low and shows high tumor-to-tumor variability ( Fig.  2A) mT-mG mice and were either untreated or treated with tamoxifen (TAM) 14 weeks p.i. to activate CreER T2 in SPC positive cells and euthanized 6 weeks later. Occasional EGFPpositive tumors (<5%) were detected in the absence of TAM, which suggests some leakiness of the SPC CreER transgene (Fig. 4A) . However, in TAM-treated mice, almost all of the BRAF V600E -initiated lung tumors contained EGFP-positive cells (Fig. 4A) -initiated lung tumor cells (Fig. 4B) . Lung tumor burden was assessed in both groups of mice 8 weeks later. As anticipated, SPC CreER mediated induction of c-MYC T58A expression allele led to a significant increase in overall tumor burden (P < 0.05) and proliferation as gauged by Ki67 expression (not shown) or BrdUrd incorporation (Fig. 4C) (Fig. 5A) . However, at later times following 4-HT, the level of TP53:ER expression was diminished in BPER cells (data not shown). We suspect that restoration of TP53 activity would lead to induced expression of MDM2, leading to the destabilization of TP53:ER. Consistent with this hypothesis, when BPER cells were treated with 4-HT in the presence of nutlin-3a, we noted that expression of TP53:ER was sustained. We also generated subclones of BPER cells to ensure uniform levels of TP53:ER expression and performed subsequent experiments with BPER-clone D (BPER-D), which had the highest level of TP53 expression upon treatment with 4-HT.
We first assessed the effects of TP53:ER activation on the proliferation of BPER-D cells. Addition of 4-HT or nutlin-3a to control cells, either alone or in combination, had no effect on cell proliferation or morphology ( Fig. 5A and B) . Nutlin-3a treatment of BPER-D cells did not alter cell growth relative to ethanol treatment (1.0 Â 10 6 cells vs. 1.24 Â 10 6 cells, P ¼ 0.17). By contrast, addition of 4-HT to activate TP53:ER reduced cell proliferation significantly compared with vehicle control (P < 0.05; Fig. 5B ). Moreover, when TP53:ER was activated in the presence of nutlin-3a, cell growth was reduced to 19% of that observed in vehicle treated cells (P < 0.001; Fig.  5B ). Combination treatment also elicited alterations in cell morphology such that treated cells adopted a rounded, refractile appearance (Fig. 5A ). Similar to BPER-D cells, activation of TP53 activity in BIA cells with nutlin-3a significantly reduced cell growth compared with vehicle (1.53 Â 10 5 cells vs. 1.02 Â 10 6 cells, P < 0.001) and also resulted in a rounded, refractile morphology (Fig. 5B) .
BPER-D cells treated with vehicle, 4-HT, nutlin-3a, or the combination were analyzed by immunoblotting to assess TP53: ER activation and expression of a subset of TP53-regulated genes. Expression of TP53:ER was detected in either vehicle or nutlin-3a-treated cells, but there was no expression of the TP53 targets MDM2 and p21 CIP1 (Fig. 5C ). Treatment of BPER-D cells with 4-HT-activated TP53:ER and expression of MDM2 and p21 CIP1 . However, due to activation of the regulatory-feedback loop through MDM2, TP53:ER expression was reduced at later time points. By contrast, combined treatment with 4-HT and nutlin-3a led to robust total and serine 166 phosphorylated MDM2 and p21 CIP1 expression, in addition to sustained TP53 levels. In addition, we observed a modest reduction in p19 ARF expression, which is thought to be an indirect target of TP53 activity. These results suggest that maximal activation of TP53 in BPER-D cells requires combined treatment with 4-HT and nutlin-3a for MDM2 inhibition.
We next assessed the effects of TP53 activation on the division cycle of BPER-D or BIA cells. Cells were treated as above and labeled with BrdUrd and propidium iodide to assess transit through S-phase and cell-cycle distribution. Consistent with the proliferation assays, activation of TP53:ER (with 4-HT) led to a reduction in BrdUrd incorporation from 47.5% to 20% (Fig. 5D) . Although nutlin-3a had no effect on its own, it dramatically potentiated the effects of TP53:ER activation reducing BrdUrd-positive BPER-D cells to 0.34%. In addition, treatment of TP53 proficient BIA cells led to a reduction in BrdUrd-positive cells from 48% to 1.95% (Fig. 5D ). As expected, the reduction of BrdUrd-positive BPER-D or BIA cells was accompanied with a concomitant increase in G 1 . Most importantly, addition of 4-HT or nutlin-3a, either alone or in combination, had no effect on the cell-cycle profile in parental BP cells (data not shown).
Overall, we interpret these data to mean that reactivation of TP53 activity leads to the arrest of the BPER-D and BIA cell cycle. As removal of the inducers of BIA or BPER-D growth arrest led to commencement of cell growth, the growth arrest is reversible and therefore not a senescence-like growth arrest (Fig. 5E and data not shown). The magnitude of the antiproliferative effect is limited in BPER-D cells by the ability of TP53:ER to induce MDM2 that serves to inhibit the expression/activity of TP53:ER. However, when TP53:ER is activated in the presence of nutlin-3a in BPER-D cells, TP53:ER is unopposed by MDM2 and free to elicit its maximum growth suppressive properties. It is noteworthy that, even with maximal activation of TP53, we detected little to no evidence of TP53-induced apoptosis in BIA or BPER-D cells, respectively. Of interest, the ability of TP53 to induce cellcycle arrest does not require p19 ARF expression, which is absent from BIA cells due to Cre-mediated silencing of the Cdkn2a locus (Fig. 3C ).
TP53 activation does not enhance death of BRAF V600E /INK4A-ARF
Null cancer cells when combined with MEK inhibition The ERK1/2 MAP kinase pathway is reported to promote transcriptional activation of MDM2 and consequently dampen the effects of TP53 in cells (25) . Therefore, we tested the combined effects of MEK1/2 inhibition (PD325901, PD901 hereafter) and TP53 activation to determine if this combination would yield more striking antiproliferative effects on cells. MEK inhibition dramatically reduced proliferation of BIA cells (1.02 Â 10 6 cells vs. 1.23 Â 10 5 cells, P < 0.001) after 48 hours (Fig. 6A ). Nutlin-3a treatment also suppressed BIA cell proliferation (1.02 Â 10 6 cells vs. 1.53 Â 10 5 cells, P < 0.001), whereas combined treatment of nutlin-3a plus PD901 further suppressed cell growth (8.6 Â 10 4 , P < 0.001). Analysis of BrdUrd incorporation revealed that, compared with control (48% BrdUrd-positive), nutlin-3a ($2%) more effectively inhibited S-phase progression than PD901 (16.7%) with the combination most effective at inhibiting BrdUrd incorporation (0.2%).
Immunoblot analysis indicated that nutlin-3a-treated BIA cells displayed increased TP53 expression with elevated expression of TP53 target genes, MDM2 and PUMA (Fig. 6C) . Despite PUMA induction, a mediator of TP53-induced apoptosis (37) , there was only a modest increase of cleaved-caspase 3 (CC3), a marker of apoptosis, in nutlin-3a-treated BIA cells. MEK1/2 inhibition with PD901 had no effect on MDM2 or PUMA expression but led to decreased TP53, elevated BIM expression, and CC3 consistent with previous reports (38) (39) (40) . However, when PD901 was combined with nutlin-3a, there was a modest diminution of both MDM2 and TP53, the significance of which is currently unclear. These results suggest that the MAP kinase pathway contributes to the TP53 regulatory loop through transcriptional activation of MDM2 as previously reported (21 activation does not enhance apoptosis observed following MEK inhibition.
Serum factors and differential TP53 threshold levels provide cell survival during reactivation of p53
Interestingly, activation of TP53 in either BPER-D or BIA lung cancer cells resulted only in a G 1 cell-cycle arrest and did not elicit senescence or apoptosis. We hypothesized that perhaps factors present in fetal calf serum (FCS) may provide survival signals as well as contribute to the regulation of TP53 and/or its downstream targets. Therefore, we cultured BIA cells in either full (10%) or low (0.5%) serum conditions and then activated TP53 with nutlin-3a in the absence or presence of PD901. As expected, TP53 activation in full serum led to inhibition of cell proliferation. By contrast, TP53 activation in cells cultured in low serum displayed signs of cell death as evidenced by the presence of numerous floating cells (Fig. 7A) . PD901 treatment in the absence or presence of nutlin3a-enhanced cell death under low FCS conditions (Fig. 7A ).
Cell lysates were prepared from BIA cells, cultured in 10% versus 0.5% FCS, that were treated for 6, 15, or 30 hours with nutlin-3a, PD901, or the combination of both agents (Fig. 7B) . Although TP53 expression was elevated in response to nutlin-3a in both conditions, the magnitude of TP53 expression was higher under low serum at 15 and 30 hours post-nutlin-3a addition (Fig. 7B) . Again, PD901 led to substantial inhibition of pERK as early as 6 hours under both conditions. Interestingly, whereas nutlin-3a treatment of BIA cells in 10% FCS failed to elicit CC3 activation at any time point analyzed, CC3 was readily detectable in response to nutlin-3a in BIA cells cultured in low serum. Combined treatment with PD901 plus nutlin-3a led to the expected induction of CC3, which was again further increased under low FCS conditions. Indeed, we were unable to isolate sufficient cell lysates from BIA cells cultured in low serum and subjected to combination PD901 plus nutlin-3a treatment to analyze by immunoblotting. These results are consistent with the hypothesis that the presence of serum factors can gate signals elicited by activated TP53 that, in turn, contribute to whether a cell will commit to apoptosis. Furthermore, it has been suggested that high levels of TP53 are required to induce apoptosis, which may not be achieved under full serum conditions (41) .
Discussion
GEM models of cancer have generated a wealth of knowledge regarding the genetics, cell biology, and biochemistry of cancer initiation and progression (42) . They have also shed new insights on therapeutic intervention for cognate human diseases (15, 43) . Although the earliest GEM models relied on constitutive expression of activated oncogenes, recent models place an emphasis on temporal and spatial control of physiologically relevant levels of oncogene expression and appropriate cell of origin (15, 44) . Moreover, although tumor initiation may be driven by a single mutational event, malignant progression generally requires multiple cooperating genetic or epigenetic events, in particular oncogene activation combined with silencing of tumor suppressors. Thus, more complex and sophisticated models in which multiple cooperating genes can be modified in adult mice using sequencespecific DNA recombinases such as Cre, Flp, or Sleeping Beauty have become more common (45, 46) . A frequent drawback of using such models is that the genetic events that fuel tumor initiation and cancer progression are regulated by the same recombinase such that oncogene activation and TSG silencing occur simultaneously, a rare situation in the genesis of human cancers.
We and others have previously described the utility of mice carrying Cre-activated alleles of Braf in various GEM models (8) (9) (10) (47) (48) (49) (50) . To complement this approach, we now describe the generation of mice carrying a Braf allele (Braf -induced benign tumors (8) . Ultimately, we will have to test the cancer-promoting effects of selective silencing of either INK4A or ARF using suitably manipulated GEM models (52, 53) .
The Braf FA mouse model also provides an opportunity to model the effects of TP53 silencing prior to BRAF V600E expression, a situation that may occur in Li-Fraumeni patients (12, 13) . TP53 silencing prior to BRAF V600E expression appeared to modestly increase the multiplicity of large lung adenocarcinomas. Although TP53 silencing has no overt effect on lung epithelial cells on its own, it may potentiate BRAF V600E -induced lung carcinogenesis through effects on oncogeneinduced senescence or through effects on putative stem cells of origin of lung cancer, effects on genomic instability or cell metabolism. We must also consider the less interesting possibility that TP53-deficient lung epithelial cells are more susceptible to Flp-mediated recombination of the Braf FA allele and thereby better elicit its oncogenic effects.
Previous work employing GEM models demonstrated that restoration of TP53 expression in KRAS G12D /TP53 Null lung cancer led to modest regression of high-grade lesions that required the expression of p19 ARF . These data suggest that sustained RAF!MEK!ERK signaling driven by oncogenic KRAS G12D in high-grade lesions promoted p19 ARF expression that, in the absence of TP53, had no strong tumor suppressive effect. Although most of the tumor cells expressed restored TP53, inhibition of cell proliferation only occurred in cells with elevated RAF!MEK!ERK signaling and high ARF expression. This was supported by observations that restoration of TP53 expression in cultured KRAS G12D /TP53 Null lung cancer-derived cell lines elicits a G 1 cell-cycle arrest that was also p19 ARF dependent (22, 23 ARF . Although restored TP53 expression induced proapoptotic proteins such as PUMA, there was no evidence of apoptosis per se unless TP53 was activated in cells cultured in low serum. These observations are consistent with the fact that FCS contains mitogenic factors such as lysophosphatidic acid and sphingosine-1-phosphate that appear to protect cells from TP53-induced apoptosis. However, these factors are insufficient to sustain the cell division cycle following TP53 activation. Indeed, the induction of G 1 cell-cycle arrest by TP53 may actually provide some protection against cell death in this context. It has also been reported that the levels of TP53 may play a role in determining cell fate (41) and our observation of low TP53 induction in full FCS may explain cell survival through growth arrest, rather than apoptosis. Restoration of TP53 in the face of growth factors in humans may provide a survival mechanism for tumor cells by inducing a protective growth arrest instead of cell death.
In summary, we describe a new GEM model for exploring the consequences of the temporal dissociation of BRAF V600E expression from additional cooperating events such as sustained expression of c-MYC expression or silencing of the TP53 or INK4A-ARF tumor suppressors. This model is particularly useful in the lung, where the availability of viral vectors for expression of Flp recombinase can be combined with a knock-in SPC Cre:ER transgene to allow ready temporal dissociation of genetic events. Moreover, the Braf FA mice will likely prove useful for extending our knowledge of the mechanisms of tumorigenesis in the wide variety of GEM models of human cancer based on conditional BRAF V600E expression (9, 10, 47, 48, 54) .
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